Law360, New York (October 7, 2015, 8:29 PM EDT) -- A Pennsylvania federal court Wednesday threw out a failure-to-warn suit against Novartis claiming its high blood calcium treatment Zometa caused a serious bone disease in the jaw of a now-deceased patient, ruling his estate and doctors were properly warned of the drug's risks.
The estate of William Bock had sued Novartis Pharmaceuticals Corp., claiming that he took Zometa to combat hypercalcemia but that the drug caused osteonecrosis of the jaw, or ONJ, a serious bone disease, according to the opinion. The drugmaker allegedly did not adequately warn that its FDA-approved treatment, designed to manage metastatic bone cancer among other things, could...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!